Cargando…

Case Report: Favorable Response and Manageable Toxicity to the Combination of Camrelizumab, Oxaliplatin, and Oral S-1 in a Patient With Advanced Epstein–Barr Virus-Associated Gastric Cancer

Some pertinent studies have demonstrated that Epstein–Barr virus-associated gastric cancer (EBVaGC) patients showed a favorable clinical outcome to immunotherapy and Epstein–Barr virus (EBV)-positive status might be a potential biomarker for immunotherapy in gastric cancer (GC). However, knowledge o...

Descripción completa

Detalles Bibliográficos
Autores principales: Lv, Wanrui, Cheng, Ke, Li, Xiaofen, Feng, Lusi, Li, Hancong, Li, Jia, Chang, Chen, Cao, Dan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8791849/
https://www.ncbi.nlm.nih.gov/pubmed/35096571
http://dx.doi.org/10.3389/fonc.2021.759652
_version_ 1784640274247450624
author Lv, Wanrui
Cheng, Ke
Li, Xiaofen
Feng, Lusi
Li, Hancong
Li, Jia
Chang, Chen
Cao, Dan
author_facet Lv, Wanrui
Cheng, Ke
Li, Xiaofen
Feng, Lusi
Li, Hancong
Li, Jia
Chang, Chen
Cao, Dan
author_sort Lv, Wanrui
collection PubMed
description Some pertinent studies have demonstrated that Epstein–Barr virus-associated gastric cancer (EBVaGC) patients showed a favorable clinical outcome to immunotherapy and Epstein–Barr virus (EBV)-positive status might be a potential biomarker for immunotherapy in gastric cancer (GC). However, knowledge of given exposure to EBVaGC to the first-line immunotherapy is largely inadequate. Moreover, whether camrelizumab can be as effective as other PD-1 inhibitors in the treatment of advanced EBVaGC has not been reported. We report a case of advanced EBVaGC patient with a positive expression of PD-L1, enriched PD-L1+CD68+macrophages, and high TMB who had a long-term partial response and manageable toxicity to the combined approach of camrelizumab (a novel PD-1 inhibitor) and oxaliplatin plus oral S-1 (SOX). As the first-line treatment of advanced EBVaGC patients, camrelizumab combined with SOX regimen may provide a novel combined approach with favorable response and manageable safety. Combination of multiple biomarkers could have a higher effective predictive capacity to immunotherapy. Integrated treatment (chemo-immunotherapy and radiotherapy) might be the optimal strategy for patients with oligometastasis. It deserves prospective research to further validate the efficacy.
format Online
Article
Text
id pubmed-8791849
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-87918492022-01-28 Case Report: Favorable Response and Manageable Toxicity to the Combination of Camrelizumab, Oxaliplatin, and Oral S-1 in a Patient With Advanced Epstein–Barr Virus-Associated Gastric Cancer Lv, Wanrui Cheng, Ke Li, Xiaofen Feng, Lusi Li, Hancong Li, Jia Chang, Chen Cao, Dan Front Oncol Oncology Some pertinent studies have demonstrated that Epstein–Barr virus-associated gastric cancer (EBVaGC) patients showed a favorable clinical outcome to immunotherapy and Epstein–Barr virus (EBV)-positive status might be a potential biomarker for immunotherapy in gastric cancer (GC). However, knowledge of given exposure to EBVaGC to the first-line immunotherapy is largely inadequate. Moreover, whether camrelizumab can be as effective as other PD-1 inhibitors in the treatment of advanced EBVaGC has not been reported. We report a case of advanced EBVaGC patient with a positive expression of PD-L1, enriched PD-L1+CD68+macrophages, and high TMB who had a long-term partial response and manageable toxicity to the combined approach of camrelizumab (a novel PD-1 inhibitor) and oxaliplatin plus oral S-1 (SOX). As the first-line treatment of advanced EBVaGC patients, camrelizumab combined with SOX regimen may provide a novel combined approach with favorable response and manageable safety. Combination of multiple biomarkers could have a higher effective predictive capacity to immunotherapy. Integrated treatment (chemo-immunotherapy and radiotherapy) might be the optimal strategy for patients with oligometastasis. It deserves prospective research to further validate the efficacy. Frontiers Media S.A. 2022-01-13 /pmc/articles/PMC8791849/ /pubmed/35096571 http://dx.doi.org/10.3389/fonc.2021.759652 Text en Copyright © 2022 Lv, Cheng, Li, Feng, Li, Li, Chang and Cao https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Oncology
Lv, Wanrui
Cheng, Ke
Li, Xiaofen
Feng, Lusi
Li, Hancong
Li, Jia
Chang, Chen
Cao, Dan
Case Report: Favorable Response and Manageable Toxicity to the Combination of Camrelizumab, Oxaliplatin, and Oral S-1 in a Patient With Advanced Epstein–Barr Virus-Associated Gastric Cancer
title Case Report: Favorable Response and Manageable Toxicity to the Combination of Camrelizumab, Oxaliplatin, and Oral S-1 in a Patient With Advanced Epstein–Barr Virus-Associated Gastric Cancer
title_full Case Report: Favorable Response and Manageable Toxicity to the Combination of Camrelizumab, Oxaliplatin, and Oral S-1 in a Patient With Advanced Epstein–Barr Virus-Associated Gastric Cancer
title_fullStr Case Report: Favorable Response and Manageable Toxicity to the Combination of Camrelizumab, Oxaliplatin, and Oral S-1 in a Patient With Advanced Epstein–Barr Virus-Associated Gastric Cancer
title_full_unstemmed Case Report: Favorable Response and Manageable Toxicity to the Combination of Camrelizumab, Oxaliplatin, and Oral S-1 in a Patient With Advanced Epstein–Barr Virus-Associated Gastric Cancer
title_short Case Report: Favorable Response and Manageable Toxicity to the Combination of Camrelizumab, Oxaliplatin, and Oral S-1 in a Patient With Advanced Epstein–Barr Virus-Associated Gastric Cancer
title_sort case report: favorable response and manageable toxicity to the combination of camrelizumab, oxaliplatin, and oral s-1 in a patient with advanced epstein–barr virus-associated gastric cancer
topic Oncology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8791849/
https://www.ncbi.nlm.nih.gov/pubmed/35096571
http://dx.doi.org/10.3389/fonc.2021.759652
work_keys_str_mv AT lvwanrui casereportfavorableresponseandmanageabletoxicitytothecombinationofcamrelizumaboxaliplatinandorals1inapatientwithadvancedepsteinbarrvirusassociatedgastriccancer
AT chengke casereportfavorableresponseandmanageabletoxicitytothecombinationofcamrelizumaboxaliplatinandorals1inapatientwithadvancedepsteinbarrvirusassociatedgastriccancer
AT lixiaofen casereportfavorableresponseandmanageabletoxicitytothecombinationofcamrelizumaboxaliplatinandorals1inapatientwithadvancedepsteinbarrvirusassociatedgastriccancer
AT fenglusi casereportfavorableresponseandmanageabletoxicitytothecombinationofcamrelizumaboxaliplatinandorals1inapatientwithadvancedepsteinbarrvirusassociatedgastriccancer
AT lihancong casereportfavorableresponseandmanageabletoxicitytothecombinationofcamrelizumaboxaliplatinandorals1inapatientwithadvancedepsteinbarrvirusassociatedgastriccancer
AT lijia casereportfavorableresponseandmanageabletoxicitytothecombinationofcamrelizumaboxaliplatinandorals1inapatientwithadvancedepsteinbarrvirusassociatedgastriccancer
AT changchen casereportfavorableresponseandmanageabletoxicitytothecombinationofcamrelizumaboxaliplatinandorals1inapatientwithadvancedepsteinbarrvirusassociatedgastriccancer
AT caodan casereportfavorableresponseandmanageabletoxicitytothecombinationofcamrelizumaboxaliplatinandorals1inapatientwithadvancedepsteinbarrvirusassociatedgastriccancer